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1. Introduction 
Direct involvement of CD4+ T cells in the pathogenesis of inflammatory glomerulonephritis 
such as Anti-GBM glomerulonephritis and other glomerular diseases of autoimmune 
nature, has been well demonstrated. Unlike antibody mediated mechanisms, regulation 
and/or activation of T cells requires antigen presenting cells (APC) such as dendritic cells 
(DC). DCs are critical for activation of pathogenic T cells, or for establishing T cell-mediated 
glomerular inflammation by presenting local self antigens to pathogenic T cells. Thus, recent 
studies have been focusing on identification of DCs and their functions in various human 
autoimmune glomerulonephritis or in animal models. Similar to other human autoimmune 
diseases, DCs involved in glomerulonephritis include diverse subpopulations, which have 
either pro- or anti-inflammatory functions. Understanding especially their anti-
inflammatory function may lead to development of new therapeutic strategies by 
mimicking those natural mechanisms. Mounting evidence shows the presence of tolerogenic 
DCs (tDCs) in various kidney diseases, which are involved in inhibition of autoimmunity by 
elimination or skewing development of self reactive T cells. Several new types of DCs have 
been characterized in animal models. Among them, one type of tDC may arrest an existing 
glomerular inflammatory process. This novel tDC specifically infiltrates glomeruli under 
autoimmune attack and induces apoptosis in auto-reactive T cells, leading to natural 
recovery in certain strains of animals. Thus, this tDC is an attractive target in cellular 
immunotherapy for glomerulonephritis by mimicking this natural recovery mechanism. 
2. What are dendritic cells (DCs)?  
Adaptive immunity, which is unique to vertebrates, is much more efficient than innate 
immunity, which is common among all types of animals. The high effectiveness of adaptive 
immunity is due to its specifically defined recognition of any given antigen. Only two types 
of immune cells in adaptive immunity, B cells and T cells, are capable of such antigen 
recognition through specified receptors. In T cells, their antigen recognition receptor is the T 
cell receptor (TcR); in B cells, their receptor is called the B cell receptor (BcR), which in fact is 
a membrane-bound antibody. Unlike innate immunity, B cells and T cells do not 
discriminate molecular motifs of microbial antigens from other antigens, and thus, they do 
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not directly recognize microbial antigens, or in a broader meaning, any antigens, by 
themselves. Rather, they acquire antigen-recognition capacity through “education” by other 
immune cells. The most important process during “education” is antigen presentation, 
which is carried out by so-called antigen presenting cells (APCs).  In this chapter, we will 
focus solely on APCs for CD4+ T cells, since CD4+ T cells play a central role in adaptive 
immunity, inflammatory diseases and autoimmunity including those occurring in 
glomeruli. A group of phagocytes can present antigens to CD4+ T cells (although B cells can 
act as APC to CD4+ T cells, it will be excluded in this chapter). We call these phagocytes 
“professional” APCs since their principal function is to present antigens.  These phagocytes, 
which include monocytes, macrophages and dendritic cells, capture especially microbial 
antigens through their motif/pattern recognition receptors such as toll like receptors (TLRs). 
The captured antigens are processed into peptides, which then are presented to CD4+ T cells 
in a complex of MHC II molecules and antigenic peptides.  Thus, these professional APCs 
function as messengers or connections between innate and adaptive immunity: they capture 
antigens from microbial pathogens and use these antigens to “educate” T cells and B cells. 
As a result, a group of T or B cells which solely recognize this antigen would be activated to 
fight the original pathogens in a more effective way.   
The DCs has been recognized as the most potent professional APCs since its discovery three 
decades ago.  So far, immunologists believe that DCs are the only APCs that are able to 
initiate/direct an adaptive immunity by activation of  naïve T cells, because DCs express 
special signaling molecules called co-stimulatory molecules, such as CD80 and CD86, in 
addition to their superb capacity in capturing and presenting antigens (1). From this point of 
view, DCs are also considered a critical immunoregulator.  DC was first identified as a 
population of striking dendritic-shaped cells in the spleen by Ralph Steinman in the 1970s 
(2). It soon became clear that cells similar to the splenic DCs are present in all lymphoid and 
non-lymphoid tissues, though in a much smaller number than macrophages. However, soon 
immunologists realized that DCs in fact are a heterogenic group of phagocytes, which may 
be generated from different lineages. It seems less arguable that DCs are generated from 
bone marrow stem cells. As many distinct subtypes of DCs have been described or 
discovered, it seems difficult to give a simple definition for DCs.     
What are DCs? Why did we name certain immune cells DCs?  There are several common 
characteristics shared by the cells, which have been named as DCs (3). First, DCs are usually 
of hematopoietic origin and grow branched projections called dendrites that give the cell its 
name (δένδρον or déndron in Greek means “tree”) at certain development/activation 
stages. Development of cellular projections greatly increases their cell surface area for 
contacting/ capturing antigens. Second, they are potent professional APCs, and in many 
cases, they can activate naïve T cells. Their APC function can be reflected by their expression 
of MHC II, which can be further up-regulated after stimulations, in addition to “dendrite’ 
like cellular projections, which would increase the cell surface area for capturing antigens. In 
some DCs or at certain activation stages, they also express co-stimulatory molecules for T 
cells (4). Third, they also express multiple “pattern recognition receptors” such as TLRs for 
recognition of microbial antigens.  
Different DCs migrate following a special pattern through circulation, tissue and lymphoid 
organs (Figure 1) (5). Thus, they express certain sets of chemokine receptors and adhesion 
molecule. For example, all mouse DCs express an adhesion molecules CD11c.  Immature 
DCs or DC precursors are often found in the peripheral blood before they exit the 
circulation. As a first line of immune defense, DCs, such as conventional DCs, are present in 
tissues in contact with the external environment, such as the skin and the mucosal system. 
www.intechopen.com
 
Dendritic Cells: Two-Edged Swords in Pathogenesis of Autoimmune Glomerulonephritis 
 
221 
They are actively motile and continuously sample their surroundings. Once activated after 
encountering invading pathogens or antigens, they migrate to the lymphoid organs where 
they interact with T cells and B cells to initiate and shape the adaptive immune response. 
However, this typical migration route may not fit to all types of DCs. For example, 
plasmocytoid DCs directly enter lymph nodes (6).   
 
 
Fig. 1. Schematic diagram shows circulation of DCs, from bone marrow progenitors, 
precursor in circulation and immature DCs in peripheral tissues and mature DCs  
in lymphoid organs. This route is representative. Not all DCs migrate or mature as  
shown.  
3. DC classification 
Because of the high levels of heterogeneity among identified subsets or types of DCs, their 
classification is not an easy task for immunologists. DCs have been grouped by their 
function, lineage, markers, and migration route or residing tissues. First, DCs can be 
grouped by their locations and migration route. DCs and DC precursors can be found in the 
circulation, and in different anatomic locations, including lymphoid or non-lymphoid 
tissues. Langerhans cells are a well characterized DC residing in the skin (7). DCs in the 
interstitial tissue including renal tissue are named IntDC. DCs also populate the entire 
mucosa system. Those tissue-residing DCs develop from DC precursors in the circulation, 
and act as “scouts” to detect any invading antigens. Once loaded with antigens, those DCs 
migrate into afferent lymph, and they are called veiled cells. After migrating through the 
afferent lymphatic system, they are called interdigitating DCs (IDCs) in T cell areas in the 
paracortex of lymph nodes. IDCs may activate naïve T cells there. In lymphoid tissue, many 
DCs are present in the Germinal Center (GC, where B cells differentiate) and are called GC 
DCs, which function as a strong APC for activating T cells and B cells. In GC, there is a type 
of cell called follicular DC (fDC). fDC presents antigens to B cells using a totally different 
mechanism, and thus, is not a typical DC discussed in this chapter.  Second, DCs have been 
classified by their lineage (8). For example, the terms “lymphoid DC” and “myeloid or 
monocyte-related” DC are used for those DCs, which probably differentiate from the same 
bone marrow stem cells as lymphocytes or monocytes, respectively. However, this 
classification is largely based on similarity in morphology and surface markers between the 
cells. Results from in vitro differentiation experiments or experiments to identify special 
differentiation pathways in bone marrow stem cells or DC precursors have provided some  
evidence to support some DCs’ lineage. Third, more accurate classifications of DCs that are 
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based on a combination of their lineage, markers and function, and thus, are much more 
complicated, as well as some times controversial. There are several classification methods 
for mouse DCs, since various DCs have been well characterized in mice. It seems impossible 
for this chapter to cover all those classifications for DCs. Furthermore, those classifications 
may not be able to recover or describe several newly discovered DCs. To avoid confusion, 
this chapter will mainly introduce one representative classification for mouse DCs which 
reside in the lymphoid organs, recently summarized by Sato and Fujita (9). Despite the 
difficulty in comparison of the DC systems between humans and mice, recent work has 
revealed much common ground (10).  We will then compare mouse DCs to their human 
counterparts.   
Mouse DCs are primarily defined by their surface MHC II and CD11c in combination with 
CD4, CD8, CD11b (a myeloid marker) and several other molecules such as CD205 (IDC 
marker). CD8+ DC has been classified as lymphoid DCs, while CD8- DC as myeloid 
DCs, due to their possible lineage. However, currently, both mouse and human DCs are 
divided into two big groups: conventional DCs (cDC) and plasmacytoid DCs (pDC) (Figure 
2). DCs from two groups not only show different migration routes, but also differentiate 
probably from different stem cells with quite different functions. In mice, DCs in lymphoid 
organs have been best characterized. Mouse cDCs in lymphoid tissues can be further 
divided into five subsets largely based on their CD4 and CD8 expression and their location 
in different lymphoid tissues. There are three subsets of cDCs in the spleen, which include 
two of myeloid origin with phenotypes of CD4+CD205−CD11b+ and 
CD4−CD8α−CD205−CD11b+, and one of lymphoid origin with a phenotype of 
CD8α+CD205+CD11b− (Figure 2)(11).   It needs to be pointed out that “myeloid origin” in 
this chapter are not equal to “myeloid DC (mDC)”, which has been widely used in other 
classification methods. We will explain the difference later. Each subset shows various 
functions, which are demonstrated largely by in vitro experiments (Figure 2). Both DC 
subsets of myeloid origin (i.e. CD11b+) in the spleen (some times in lymph nodes as well) 
express F4/80 (a well known marker for mature macrophages). F4/80+ cDCs are located in 
the marginal zone between white and red pulp and will migrate to the T-cell area after 
stimulation. Both splenic CD8- DCs of myeloid origin are able to stimulate CD4+ and 
CD8+ T cells and to initiate a Th2-type T cell response (12). Splenic DCs of lymphoid origin 
(CD8α+CD205+CD11b−) are found in the T-cell area; a smaller number of this cDC may also 
exist in lymph nodes. Interestingly, this DC is a dominant subset among thymic DCs. 
Several in vitro experiments showed that this cDC can function both as a regulator and 
stimulator of T cells. Although it can stimulate both CD4+ and CD8+  T cells, it subsequently 
restricts T cell proliferation by either inducing apoptosis in CD4+ T cells, or limiting 
endogenous cytokine production in CD8+  T cells. Those results suggest that this cDC subset 
may be responsible for maintenance of T cell tolerance in lymphoid organs in the absence of 
infection (13). In contrast, other studies suggest this subset cDC to be a potent T cell 
stimulator. This CD8+  lymphoid cDC can activate both CD4+ or, through cross-
presentation, CD8+ cytotoxic T cells. More importantly, this DC can trigger the development 
of a Th1 response in vivo, which is in agreement with the fact that activated CD8+ 
lymphoid cDCs are the major source of the Th1-promoting cytokine interleukin-12 (IL-
12)(14). In addition to the above three subsets of DCs, there are two extra myeloid DC 
subsets only found in lymph nodes (Figure 2). In fact, these cDCs are mature DCs which 
have migrated from peripheral tissues to lymph nodes through the lymphatic system after 
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they are loaded with antigens. The first subset has a CD4−CD8α−CD205+CD11b+ phenotype, 
which is the mature form of interstitial tissue DCs (IntDCs), and the second subset is 
CD8αlowCD205+CD11b+, which matures from skin-associated Langerhans cells. Migration of 
Langerhans cells is restricted to the skin-draining lymph nodes, and thus, 
CD8αlowCD205+CD11b+ cDCs are found only in skin draining lymph nodes. On the other 
hand, IntDCs associated CD4−CD8α−CD205+CD11b+ cDC may be found in all lymph nodes.  
Because of their migration to lymphoid tissues, Langerhans cells and IntDCs are often called 
“migratory DCs”. Mature Langerhans cells (i.e. the CD8αlowCD205+CD11b+ cDC subset) in 
lymph nodes express characteristic langerin together with high levels of MHC II and co-
stimulatory molecules, representing a typical fully activated DC, which can effectively 
stimulate naïve CD4+ T cells to differentiate into Th1 T cells (15). A constant migration of 
interstitial tissue immature DC to lymph nodes occurs even in the absence of invading 
pathogens at steady-state. Since presentation of antigens by immature or semi-mature DCs 
may lead to unresponsiveness of T cells, the migration of tissue DCs at a steady-state is 
believed to be critical for the DCs’  involvement in the maintenance of peripheral tolerance 
(16). Before we sum up the classification of cDCs, it is necessary to clarify the terms “myeloid 
DCs (mDCs)” from DCs with “myeloid origin” described above. The term mDC has been 
widely used to describe a subset of DCs, which are believed to be from the same lineage of 
monocytes or macrophages. Some studies revealed that mDCs have at least two subsets: very 
common mDC-1 and rare mDC-2. However, more recent studies suggest that the mDCs are 
most likely equivalences of subsets of cDC with myeloid origins in the above classification. For 
example, mDC is the major source of IL-12. Several recent studies also thought the concept of 
mDC to be inappropriate (17). Thus, we try to avoid using the term mDC.  
pDC is a distinct type of DC, which is characteristically different from cDCs (Figure 2).  
pDCs are found mainly in the spleen, as well as in bone marrow, thymus and lymph 
nodes (18).  Historically, pDC was first identified in humans, which shared several 
characteristics with plasma cells (terminally differentiated B cells which secrete 
antibodies)(19). In fact, freshly isolated pDCs have a morphology which is big and round 
with only a few dendrites and very different from that of a typical DC. Furthermore, 
pDCs express B220 (a marker for mouse B cells) and Gr-1, together with CD8α, CD11c, 
CD205 and MHC II. Recently, additional surface markers, such as mPDCA-1 for mouse 
pDCs have been identified. While cDC subsets migrate into lymph nodes from tissues, 
pDCs enter lymph nodes directly from circulation by crossing the high endothelial venule 
(HEV) using the adhesion molecule CD62L. Freshly isolated pDCs lack expression of co-
stimulatory molecules, and show poor capacity to stimulate naïve T cells, suggesting their 
potential role in the maintenance of peripheral tolerance under steady-state conditions. 
Although in vitro activated pDCs are capable of simulation of T cells by up-regulation of 
expression of MHC II, CD8α, and co-stimulatory molecules, this capacity is not in the 
range compatible to that of cDCs. On the other hand, mouse pDCs produce a large 
quantity of type I interferon (IFN) following a viral infection, suggesting its important 
role in antiviral responses rather than the APC function in initiation of a T cell response 
(10, 20). The lineage of mouse pDCs remains controversial. Recent studies showed 
complicity of pDC lineage, suggesting that its precursor cell may represent a unique 
hematopoietic lineage with high flexibility in its differentiation.  Nevertheless, Flt3L (a 
cytokine) has been identified to be a major cytokine for the development of pDCs from 
hematopoietic stem cells (21).   
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Fig. 2. Simplified classification of DC subsets in humans and mice. Each subset is named by 
its major markers. Their anatomic locations and major functions are listed for reference. 
Arrows indicate differentiation direction. IDC, interdigitating DC; IntDC, interstitial tissue 
DC; IPC, natural IFN-producing cell; LC, Langerhans cell; LN, lymph node.        
Human DCs, especially those residing in the lymphoid organs, have not been characterized 
as well as those in mice because peripheral blood samples or, in some cases, fetus umbilical 
cord blood samples, are some times the only readily available source. In rare cases, 
investigators used human DCs isolated from lymphoid tissues, ranging from the tonsil, 
thymus, and spleen. Thus, human DCs from peripheral blood will be discussed for their 
classification. Similar to mouse DCs, human DCs also fall into two distinct groups: human 
cDC and pDC (9). Although all human cDCs express CD11c, human pDC does not. Thus, 
unlike for mouse DCs, CD11c is not a common marker for human DCs. In addition, because 
of a lack of available materials, migration route and maturation of human DCs are less 
understood. More studies are needed. Nevertheless, for human cDCs, two subsets with 
myeloid origin have been described in peripheral blood samples thus far, both of which co-
express CD11b and CD11c (Figure 2). In addition to common CD11b, CD11c, CD4, and 
MHC II, the two human cDCs in the blood can be distinguished by other markers: the 
CD1a+BDCA-1/CD1c+ CD11chigh subset and the CD1a−BDCA-3/CD141+ CD11clow subset 
(22, 23).  These two human myeloid cDC subsets show the capacity to stimulate T cells; this 
capacity will be further augmented in the presence of the cytokine granulocyte-macrophage 
colony stimulating factor (GM-CSF).  In vitro experiments showed that under certain culture 
conditions, these CD1a+BDCA-1/CD1c+ CD11chigh subset would differentiate into the cells, 
which expressed several molecules such as langerin and displayed typical Birbeck granule 
characteristics of Langerhan cells, suggesting this subset to be the precursor of Langerhans 
cells. On the other hand, the CD1a−BDCA-3/CD141+ CD11clow subset may be the direct 
precursors of IntDCs (24). However, this classification is merely based on markers, and may 
not reflect their lineage but their maturation status. As described above, these two human 
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cDC subsets in the blood, in fact, are precursors of cDCs before their migration into tissue. 
Therefore, it is difficult to compare human cDCs to mouse cDCs, because of different 
locations. 
Human pDCs share many common features with mouse pDCs.  As we mentioned above, 
pDCs were first identified in humans as a rare type of cells in the paracortical areas in active 
lymph nodes with a morphology similar to plasma cells. However, this cell also expressed 
several markers for T cells and monocytes, and thus, it originally was named as 
plasmacytoid T cell or plasmacytoid monocyte. Recent studies have demonstrated that 
plasmacytoid monocytes, natural IFN-producing cells (IPCs), and immature DCs in 
peripheral blood and tonsils turn out to be the same cell known as the pDCs (Figure 2). 
Similar to mouse pDCs, human pDCs are of lymphoid origin and they poorly stimulate T 
cells. However, they could differentiate into IDC-like cells and acquire the ability to activate 
naïve T cells in the presence of IL-3 and CD40L. More studies show that pDCs not only can 
provoke a Th1 or Th2 responses, but also induce immune tolerance in vivo (25).  Similar to its 
mouse counterpart, it can produce large amounts of type I IFN in response to certain viruses 
(19). Cytokines Flt3L and G-CSF are required for generation and differentiation of pDCs, 
respectively (26). Administration of Flt3L dramatically increases both myeloid cDCs and 
pDCs, whereas G-CSF only increases pDCs. 
As we described above, all identified human DCs, including cDCs and pDCs, may express 
CD4, but never CD8.  Mouse CD8+ DCs have several special functions that other DCs lack 
in regulation of the T cell response. Hence, they become a promising target for clinical 
application to manipulate immune responses in autoimmune diseases, organ grafting, and 
vaccination. Failure of decades-long searching to identify human CD8+ DCs has led to 
question whether CD8+ cDCs may exist in humans. However, a recent paper may have 
made a breakthrough in identifying a human counterpart of mouse CD8+ DC; this study 
identified a population of human DNGR-1+BDCA-3+ leukocytes in the spleen (27). Although 
this cell lacked expression of CD8, it shares many other markers/molecules, as well as 
several special functions, with mouse CD8+ DCs.  It is highly possible that this cell is 
equivalent to mouse CD8+ DCs.  
4. Roles of DCs in promoting autoimmunity and immune tolerance   
It remains not fully understood how T cells and B cells decide to mount a response to a 
given antigen. In theory, adaptive immunity is able to mount an immune response to any 
given antigen, including self antigens, because it does not discriminate self or non-self 
antigens, or microbial antigens. Yet, our adaptive immune system normally does not 
respond to self antigens. In other words, the immune system seems to “ignore” the presence 
of self antigens. However, such unresponsiveness to, or ignorance of, self antigens is neither 
natural nor inherent. Rather, it is an acquired process. The process for T cells or B cells to 
actively “ignore” the presence of an antigen is called immune tolerance. If immune tolerance 
is toward self antigens, it is simply called self tolerance.  
The immune system possesses a network of complicated tolerance mechanisms to avoid 
immune response against all potential self antigens. Self tolerance mechanisms could occur 
at three levels. The first level is evolutionary. Special molecular patterns of microbes have 
evolutionally led to the generation of pattern recognition receptors on innate immune cells, 
which effectively bind to certain microbial molecules. We will not discuss this level of 
tolerance in this chapter, as it is not related to adaptive immunity. The second level of self 
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tolerance mechanisms occurs prior to or during activation of naïve self reactive T cells. The 
mechanisms at this level would eliminate pathogenic self reactive T cells, or skew their 
activation, and thus avoid autoimmunity de novo. The majority of known self tolerance 
mechanisms act at this level. Those mechanisms can be further divided into two categories: 
central tolerance, which occurs in central lymphoid organs such as the thymus and bone 
marrow, or peripheral tolerance which occurs mainly in peripheral lymphoid organs. The 
third level of tolerance mechanisms occurs post activation of pathogenic T cells or after 
pathogenic T cells have initiated autoimmune tissue damage.  This level of tolerance is less 
explored and thus, remains largely unknown.  Failure in tolerance (or a break in self 
tolerance) to a self antigen at any level is a prerequisite for occurrence of autoimmunity.  
With capacities in both promoting and inhibiting autoimmunity, DCs are considered one of 
the most critical manipulators/regulators in autoimmunity versus immune tolerance. 
Because DCs are the only APC capable of activating naïve T cells, they first play a pivotal 
role in breaking self tolerance in T cells as well as supporting autoimmune responses during 
pathogenesis of autoimmune diseases (28-30). On the other hand, numerous studies have 
shown that subsets of DCs, or DCs at different maturation stages, function as tolerance 
inducers by down-regulation of self reactive immune responses, or by skewing activation of 
a self reactive T cell toward a phenotype related with immune tolerance (29-31). Those DCs 
are named tolerogenic DCs (tDCs) (Figure 3)(32, 33).  A single type of DCs may function as 
both an activator of an immune response or a tolerance inducer, depending on their 
maturation/activation status or even their location (33). In other cases, a special subset of 
DC may act as tDCs and play a sole role in immune tolerance.     
 
 
Fig. 3. Comparison of immunogenic DC and tolerogenic DC (tDC). Fates of T cells after their 
interaction with DCs are shown at the right. Note the differences in expression of co-
stimulatory molecules and cytokines.  TLR, Toll-like receptor; FcR, Fc receptor. 
Due to their special functions in immunoregulation, DCs have been long investigated for 
their roles in autoimmune diseases since their discovery. As mentioned in the last 
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paragraph, it is clear that DCs could be pathogenic or protective in autoimmune diseases. 
From this point of view, DCs can be divided into two groups based on their functions 
during an autoimmune response: immunogenic DCs, which provoke an autoimmune 
response to an antigen, and tDCs, which induce tolerance to an antigen. A balance between 
the two DCs is the key to determine if autoimmunity will occur. Thus, alterations in either 
DCs due to genetic milieu or environmental factors may lead to unbalance, resulting in 
autoimmunity.  
In the early years after discovery of DCs, investigations mainly focused on DCs’ function in 
promotion or initiation of autoimmunity. It seems there are no arguments that DCs are 
required to activate naïve self reactive T cells, which is a pivotal player in manifestation of 
autoimmune diseases. DCs are the only known APCs which are capable of eliciting 
autoimmune responses and/or autoimmune diseases. In addition, unique functions of DCs 
in target tissues may further enhance autoimmune inflammation through coordinating 
recruitment and activation of other immune players. Those early studies have elegantly 
provided direct evidential support that DCs are a critical player especially in the initiation 
stage of autoimmunity in animal models such as experimental allergic encephalomyelitis 
(EAE) models for multiple sclerosis (MS) and non-obese (NOD) model for Type I diabetes.  
For example, transfer of DCs, which were engineered to constitutively express a T-cell 
epitope of a model antigen, induced destruction of the islet, where this model antigen was 
expressed (34).  In an EAE model, DCs were pulsed in vitro with a T cell epitope of well 
known self antigen for MS called myelin basic protein; transfer of the DCs into untreated 
mice resulted in MS like symptoms (35). In addition, the role of DCs in autoimmune 
diseases was indirectly demonstrated, in part, by examination of DCs in tissues of human 
autoimmune patients. For example, a high number of DCs were detectable in the serum and 
synovial fluid of patients with various autoimmune diseases such as rheumatoid arthritis, 
Sjogren’s syndrome, multiple sclerosis, thyroiditis and diabetes (36-38). One study further 
showed a positive association between high levels of circulating DCs secreting pro-
inflammatory cytokines with severity of multiple sclerosis (39).  
However, unlike in an immune response to invading organisms, the mechanisms for 
activation of naïve reactive T cells by a DC in an autoimmune response are unique and thus, 
are a main focus of investigations. Several mechanisms, by which DCs activate pathogenic T 
cells, have been revealed in the past. First, DCs will mature during an infection; the mature 
DCs may co-present self antigens with those from infectious agents to naïve self reactive T 
cells. Frequent or persistent viral infections may boost the release of self antigens in the 
target organ, which in turn would greatly increase the chance for DCs to “accidently” 
activate naïve self reactive T cells.  In addition, overall anti-viral or bacterial immunity may 
generate cytokine-mediated bystander activation of self reactive lymphocytes. Second, DCs 
present some pathogenic antigens, which mimic certain self antigens, to naïve T cells. Some 
of those activated T cells may recognize self antigens and cause autoimmunity. Some 
mimicking peptides may have a low efficiency in stimulating naïve T cells due to a low 
binding affinity to their TcR. However, increased quantity of microbial antigens during 
infection could enhance engagement of more mimicking epitopes with TcR, leading to the 
activation of self reactive T cells. Third, certain defects in host tissues may lead to the release 
of increased amounts of or altered self antigens, which have been previously ignored by the 
immune system. For example, the defective clearance of apoptotic cell debris due to an 
impaired uptake may result in an autoimmunity. In this case, DCs may be activated by 
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apoptotic materials such as DNA. A recent study showed that binding of their surface TLR7 
and TLR9 to dsDNA from dead cells activates pDCs, which in turn initiate autoimmune skin 
inflammation in a murine model (40). A common feature for the above three scenarios is 
that DCs are passively involved in activation of self reactive T cells, and thus, they are 
“innocent” in those scenarios. In those cases, autoimmunity occurs mainly due to the 
increase in available self antigens. A “threshold” model has been proposed to summarize 
the above cases (41). DCs constantly present self antigens, but they fail to activate T cells 
because antigens are under a “threshold” level.  Multiple factors may influence the quantity 
of presented self antigens to surpass the threshold, resulting in a significant autoimmune 
response, and subsequently an autoimmune disease. Fourth, DCs are also regulated by other 
immune cells or molecules. DC’s maturation and development are controlled by the types of 
pathogens/antigens as well as cytokines released by the activated T cells. One study 
suggested that high levels of IFN- in systemic lupus erythematosus (SLE) may promote 
differentiation of monocytes to DCs, which in turn initiates an autoimmune response by 
picking up and further presenting more SLE-specific self antigens to self reactive T cells (42). 
Generally, regulatory T cells (Tregs) can suppress the maturation, activation and the 
subsequent production of inflammatory cytokines by recently activated DCs. However, 
chronically activated DCs, which may be presenting self antigens, could escape this 
mechanism and provoke an autoimmune response (43). Fifth, DCs could initiate 
autoimmunity because of intrinsic defects in genes controlling the DCs’ functions, which 
results in DCs that behave deviantly. There are numerous genetic defects in DCs, which 
have been associated with the onset of autoimmune diseases. Unusual differentiation 
and/or maturation of DCs may lead to an abnormality of DCs either in quantity or quality. 
Loss of integrin v8 on DCs causes autoimmunity and colitis in mice (44). Defects in the 
apoptosis of immune cells, including DCs, have been blamed for several autoimmune 
diseases. Abnormal co-stimulatory phenotypes of DCs have been linked to onset of severe 
murine lupus. By coordinating the recruitment and/or activation of other immune cells, 
DCs can drive the generation of ectopic lymphoid tissues, as in the case of inflamed synovia 
in rheumatoid arthritis (RA) and SLE. Thus, more self antigens would be presented more 
effectively in target organs. Normally, some DCs would be eliminated through apoptosis, 
because they have the potential to activate naïve self reactive T cells. However, genetic 
defects in DCs’ apoptosis may prolong DCs’ life and increase the chances for them to 
activate self reactive T cells. A transgenic mouse expressing the baculoviral caspase 
inhibitor, p35, in DCs results in their accumulation and, in turn, chronic lymphocyte 
activation and systemic autoimmune manifestations (45).   
Despite its pivotal role in provoking an autoimmune response as sole APCs that can activate 
self reactive T cells, many more studies have been devoted to exploring DC’s roles in self 
tolerance and/or autoimmunity prevention/controlling (33). It is clear now that DCs play 
critical roles in both central and peripheral tolerance. For central tolerance, thymic DCs 
function similar to but not limited to thymic epithelial cells. Both cells can selectively induce 
apoptosis in immature potential self reactive T cells. When immature T cells enter the 
thymus to be “educated”, thymic DCs as well as thymic epithelia will present self antigens 
to immature T cells. If a T cell bears TcR which binds to the self antigens with high affinity, 
DCs will selectively trigger apoptosis in these potentially self reactive immature T cells. This 
process is called “negative selection”. Unlike thymic epithelial cells, which can only present 
self antigens within the thymus, thymic DCs also can carry self antigens from outside tissues 
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to eliminate additional self reactive T cells. Furthermore, thymic pDCs or mDCs, which are 
activated by thymic stromal lymphopoietin, induce generation of natural CD4+CD25+ Treg.    
A significant number of tDC-mediated tolerance mechanisms have been demonstrated in 
both humans and animals. In general, those tDC-mediated mechanisms are much more 
complicated and sophisticated than those in central tolerance. Elucidation of the known DC-
mediated tolerance mechanisms and discovery of new ones in peripheral tissues remain a 
big challenge for immunologists, and thus, it is still a hot topic in immunological research 
today. Known tDC-mediated peripheral tolerance mechanisms, including one from our 
group, will be summarized in this section. There are two types of tDCs. The first type of 
tDCs is immature or semi-mature DCs, which are believed to be tolerogenic (33). The second 
type of tDCs are special types of DCs, or a specially differentiated DC subset, which act 
solely as an immune tolerance inducer.  For the first type of tDCs, in the absence of infection 
or inflammation, DCs in the tissues will remain in an immature state. Those immature DCs 
may also capture self antigens from dead cells or accidentally released substances from cells 
and migrate to lymphoid organs with loaded self antigens due to homeostatic traffic. Unlike 
a mature DC, the immature or semi-mature DC, which has been loaded with self antigens, 
actively silence self reactive T cells because they lack co-stimulatory molecules for a full T 
cell activation. There are several mechanisms for those immature or semi-mature DCs to 
silence naïve self reactive T cells. Just as they do in central tolerance, some DCs may induce 
apoptosis in the T cells, which recognize the self antigen presented by DCs (45). 
Alternatively, the immature DCs induce unresponsiveness in T cells called anergy. It is 
believed that homeostatic traffic of DCs to silence naïve T cells is critical for maintenance of 
peripheral tolerance (46). Defect in molecules such as chemokine receptors, which is critical 
for this homeostatic migration, has been linked to several autoimmune diseases such as 
rheumatoid arthritis (RA) and MS. Furthermore, it has been reported that immature DCs 
may stimulate naïve self reactive T cells to differentiate into regulatory T cells (Treg) (47). As 
one of the most important immunoregulators, Tregs, in turn, actively inhibit pathogenic self 
reactive T cells. Several studies suggest that Treg can also inhibit maturation of DCs, and 
thus, more tDCs are generated. On the other hand, the second type of tDCs are specifically 
differentiated DCs, or from different lineages, which have the sole function of inducing an 
immune tolerance. Mounting evidence supports the presence of such tDCs. For example, the 
treatment of DC precursors with certain substances such as glucocorticoid (GC) leads to the 
generation of a type of DC which was morphologically similar to a mature DC, but was able 
to induce T cell anergy, suggesting that an anergy-inducing DC could be a special type of 
DCs (48).  1,25-dihydroxyvitamin D3 (1,25-vitD) has been known to inhibit autoimmune 
diseases in animal models, as well as in humans. Activation of vitamin D receptor (VDR) by 
either exogenous or endogenously generated1,25-vitD reprograms DCs to become 
tolerogenic (49). An experiment showed that systemic administration of in vitro generated 
tDC with TNF- treatment ameliorates murine inflammatory arthritis, suggesting a critical 
role of cytokines from a tissue microenvironment in generation of tDC. Obviously, 
tolerogenicity of those DCs does not depend on its maturation stage but rather on their 
different maturation pathway. This is probably true for humans as well. A new phenotype 
of tDC, which induces T cell anergy, can be generated from human monocyte-derived DCs 
by treatment of proteases from the fungus Aspergillus oryzae (ASP)(50). A long list of 
substances can induce differentiation of tDCs (32). Dexamethasone-treated DCs are able to 
induce differentiation of Treg in vitro (51). Both immunologists and clinicians expect a 
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potential clinical application from the in vitro generated tDCs for inhibition of 
autoimmunity, and induction of immune tolerance to graft antigens. Some animal models 
showed encouraging results by transfer of tDC to inhibit autoimmune diseases (52). 
Vasoactive intestinal peptide induced regulatory dendritic cells showed therapeutic effects 
on autoimmune disorders (53) On the other hand, investigators are also searching for tDCs 
with a different lineage from the known cDCs or pDCs. A tDC, which is responsible for 
inhibition of CD8+ T cell mediated anti-tumor activity, has been described in a murine 
model (54).  This type of tDC has not been characterized well, and further investigation is 
needed. Our group is currently characterizing a new type of DC, which may be tolerogenic 
(55). 
The common features for the above DC-mediated tolerance mechanisms can be 
summarized as follows: 1) DCs act on naïve T cells, and 2) DCs induce tolerance in 
lymphoid tissues but not in peripheral tissues. As a result, those DCs prevent 
autoimmunity de novo, because pathogenic T cells would be eliminated from lymphoid 
tissues before their activation. However, it is highly possible that naïve autoreactive T 
cells may escape the above mechanisms and be activated to further differentiate into 
pathogenic effecter cells through, for example, molecular mimicry or bystander activation 
during an infection. In fact, the presence of activated self reactive T cells has been widely 
reported in normal human individuals and animals. Although the tDCs described above 
have potential clinical applications for treatment of autoimmune diseases, it is worthwhile 
to emphasize that all those tDCs, either in vitro induced tDCs or natural tDCs, may only 
prevent autoimmunity de novo. These tDCs have shown encouraging results with a great 
promise in animal models. In most cases, the treatment needs to be prior to the onset of 
the disease. It is, therefore, questionable if these tDCs can be used to treat an existing 
autoimmune disease, which is common in human patients. It will be equally important to 
ask if any tolerance mechanisms in target tissues are able to control autoimmune diseases 
after pathogenic autoreactive T cells have infiltrated the target tissue and caused tissue 
damage. In other words, are there any tDCs which participate in the third level of 
immune tolerance?  Fortunately, a few studies suggest the existence of tDCs in the third 
level of tolerance. In vivo depletion of pDCs by antibody to mouse pDC antigen-1 
(mPDCA-1) after the onset of the disease enhanced T cell activation in target tissue but 
not in lymphoid organs, which exacerbated CNS inflammation in a mouse EAE model 
(56). This study suggests the presence of a tissue infiltrating tolerogenic pDCs, which 
infiltrated inflamed target tissue to inhibit a pathogenic T cell response. However, it 
remains to be elucidated how this pDC inhibited autoimmune inflammation. A novel DC-
mediated mechanism has been recently described in a rat anti-GBM glomerulonephritis 
model. Unlike many other types of DCs, this DC actively infiltrates inflamed autoimmune 
target tissues and presents the self antigen locally (55). The DC selectively induces 
apoptosis in the infiltrating self reactive pathogenic T cells, which recognize the presented 
self antigen. Subsequently, T cell-mediated autoimmune inflammation is stopped. In 
contrast to many other tDC-mediated tolerance mechanisms, unique features of the above 
two are that 1) it contains the autoimmune disease after activation of self reactive T 
cells/tissue damage rather than prevents it de novo, and 2) it occurs in autoimmune target 
tissue rather than in lymphoid organs.  It is conceivable that these tDCs, which are 
involved in the third level of immune tolerance, could be more effective in treatment of an 
existing autoimmune disease.          
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5. Renal DCs in the steady-state  
As a first step to studying DCs’ role in renal physiology and pathology, many studies have 
been devoted to identification of DCs in normal renal tissue or related draining lymph 
nodes in both humans and animals (mainly mice and rats). Historically, as early as 1981, a 
mononuclear phagocyte with expression of MHC II and a “stellate” morphology was 
described to reside in the renal interstitium in mice, which probably was the first confirmed 
DC in renal tissue (57). Since then, various types of DCs have been identified in either 
steady-state or under pathological conditions mainly in mice, as well as in rats and humans 
(58-60). Compared to the DCs in other organs or tissues, renal DCs are still poorly 
understood. However, it has become clear that similar to those in other tissues or organs, 
renal DCs are comprised of highly heterogeneous subsets (Table 1). Using CX3CR1GFP+ 
transgenic mice, a network composed of a large number of CX3CR1+ cells, which are mainly 
DCs, spanning the entire tubule-interstitium and enclosing all nephrons has been observed 
(61). Further investigations have suggested that this renal DC network in the steady-state 
probably is involved in maintenance of renal homeostasis and self tolerance. In addition, 
several functional subsets of DCs have been identified in the kidney using various markers. 
Mouse renal DCs have been best analyzed among all species. Murine renal DCs can be 
primarily identified using a combination of CD11 and MHC II as markers. With other DC 
markers, at least three renal DC subsets have been characterized and classified, which have 
been summarized by Nelson and Kurts, respectively (Table 1)(58, 60). The majority of renal 
DCs belong to the first subset, which expresses the chemokine Franklin receptor CX3CR1, 
the macrophage marker F4/80, and the myeloid marker CD11b, but not CD8, suggesting 
this CX3CR1+F4/80+CD11b+CD8-  subset to be the equivalent to the IntDCs (i.e. cDCs of 
myeloid origin in lymphoid nodes) (refer to Figure 2)(10, 61, 62). This renal DC subset 
probably is the DCs, which form DC network surrounding renal tubules (61). A small 
number of the second subset is CD8+CD11c+ CD103+, which seems similar to the CD8+ 
cDCs of myeloid origin in the lymph nodes (63). Since this subset is normally observed in 
skin-associated lymph nodes and is associated with Langerhans cells in the skin, it will be 
interesting to determine their lineage and function (64). The third subset of renal DCs, which 
is rare, is similar to the pDCs with a phenotype of CD11c+CD8-B220+, suggesting that this 
may be pre-pDCs (61, 65).  Human renal DCs in normal kidneys also have been 
characterized, and several subsets have been described. At least two different HLA-DR+ 
myeloid cDC subtypes have been identified in the cortex of normal kidneys, with 
phenotypes of BDCA-1+DC-SIGN+ and BDCA-1+DC-SIGN- (66). The first subset is probably 
human cDCs of myeloid origin (see Table). In addition, a subset, which is similar to the 
pDCs with a phenotype of BDCA-2+DC-SIGN-, is also abundantly present in the renal tissue 
(66). All of those DC subsets are located in the tubulo-interstitium with a high frequency. 
These DCs often surround glomeruli, but are rarely observed within glomeruli. Among 
those subsets, BDCA-1+DC-SIGN+ DCs are most abundant and are four times as frequently 
present as BDCA-2+.  Thus, cDCs of myeloid origin are dominant in renal tissues in both 
humans and mice. In inflamed or injured renal tissue, additional subsets of DCs have been 
observed in both humans and mice. These pathology-related renal DCs will be discussed in 
the next section.   Several new types of DCs, such as IFN-producing killer DC, inflammatory 
TNF--inducible nitric oxide synthase–producing DCs, and tolerogenic IDO expressing 
DCs, have been identified (67-69). It remains unclear whether those newly defined DCs are 
presented in or recruited to renal tissues.  
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Species  Subset and phenotype Abundance  Note  
Mice 
CD8-  cDC myeloid  
CD11c+CD11b+F4/80+ B220-CX3CR1+ 
Many   IntDC 
CD8+ cDC myeloid? 
CD11c+CD11b-CD103+CD205-
Langerin+ 
Few 
= Langerhans 
cells? 
pDC 
CD11c+CD11b-CD8-B220+Gr1+ 
Few Pre-pDC 
CD8-  Pre-DC (inflammatory) 
CD11c+CD11b+F4/80+Gr-1+ 
- Non-residential? 
Humans  
cDC 
BDCA-1+DC-SIGN+ 
Many  
cDC 
BDCA-1+DC-SIGN- 
Many  
pDC 
BDCA-2+DC-SIGN- 
Few  
Table 1. Subsets of DCs in the renal tissue of mice and humans at steady state  
Due to the advancement in technologies and the increasing number of DC specific markers, 
investigators were able to examine renal DCs’ function and their lineage in detail by 
isolation of renal DCs from either animals or humans for in vitro experiments, or by using 
gene manipulated animals or bone marrow chimeras for in vivo experiments. Investigations 
on mice DCs suggest that, like other DCs, renal DCs probably also derive from common 
bone marrow stem cells for macrophages and DC precursors. Renal DCs may directly derive 
from circulating pre-DCs (59). Based on the studies on DCs in other non-lymphoid or 
lymphoid organs, these bone marrow stem cells first differentiate into circulating or 
patrolling Csf1r+Gr1+ and Csf1r+Gr1– monocytes in peripheral blood (70, 71). Subsets of 
Csf1r+Gr1– or Csf1r+Gr1+ monocytes may become the precursor of different pre-DCs under 
certain conditions. However, a study suggested the presence of non-monocyte pre-DCs for 
DCs in other tissues such as the lung (72). On the other hand, some studies showed that 
diverse renal DC populations probably differentiate from FLT3+ DC precursors for both 
pDCs and mDCs (73). Microenvironments in renal tissue may determine diversification of 
renal DCs from this rather flexible common DC precursor. One in vivo experiment showed 
that injection of FLT3 to mice did not alter the proportion of each DC subset in the kidney, 
although the DCs’ number significantly increased (74).  Very early studies also suggest a 
potential of the renal microenvironment in generation of diverse renal DCs from shared 
progenitors or precursors. Subsets of renal DCs of myeloid origin share several common 
markers among the mononuclear phagocytes such as F4/80 and CD68. This phenotypic 
overlap between renal DCs of myeloid origin and macrophages is different in different 
tissue locations within normal kidneys, suggesting that the environments may affect DCs’ 
phenotypic changes (75). In one experiment, stimulation of the same precursor by different 
cytokines led to the generation of pro- or anti-inflammatory DCs (70). GM-CFS stimulated 
DC precursors from bone marrow promotes the generation of DCs with an inflammatory 
phenotype by both ex vivo and in vivo experiments (70). On the other hand, FLT3L-derived 
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DCs are phenotypically similar to DCs at a steady state, which are believed to be mainly 
anti-inflammatory. Several studies have tried to identify the local factors which determined 
renal DCs’ differentiation. For example, CSF-1 receptor is known to be important for the 
differentiation and survival of myeloid DCs in general (76). Renal epithelial cells 
constitutively express CSF-1 (77, 78). It will be interesting to test if epithelium-expressed 
CFS-1 is involved in shaping renal DCs’ repertoire. In summary, the majority of studies on 
renal DCs of myeloid origin suggest that local inductive factors shape the repertoire of renal 
DCs.  
There are several interesting issues regarding the life cycle of renal DCs at a steady-state. 
First, how pre-DCs migrate or are recruited into renal tissues. Chemokines and adhesion 
molecules play a pivotal role in leukocyte trafficking. Thus, renal DCs or their precursors in 
the circulation are expected to express certain sets of chemokine receptors and adhesion 
molecules. Several experiments have suggested special chemokines released from renal 
tissue may be required for recruitment of pre-DCs to the kidney. However, information 
regarding expression of these two molecules in renal DCs is still lacking or controversial. 
The second issue is the life span for renal DCs. Using a bone marrow chimera mouse model, 
the life span of renal DCs in mice has been determined to be 10-14 days in homeostasis (79). 
On the other hand, BrdU-labeling experiments using normal mice suggest an average half-
life of approximately 35 days across all subsets of renal DCs (80). The third issue is whether 
renal DCs can self renewal or need to be constantly recruited from the circulation. A study 
observed that a small percent of residential leukocytes were CX3CR1highGR1-  but lacked 
markers for differentiated DCs, suggesting these to be renewal DCs (61). However, more 
experiments are needed to answer this question.  
The subsets of renal DCs, which are constantly present in normal renal tissue and form an 
immune surveillance network at a steady-state, may have three functions. However, those 
functions are largely speculated from the results for DCs in other tissues. First, they serve as 
sentinels in monitoring possible invading pathogens as one part of immune surveillance. 
Once they are activated by pathogens, mature renal DCs will migrate into renal draining 
lymph nodes to provoke an adaptive immune response against the pathogens (61, 81). 
Second, as one part of innate immunity, renal DCs may release cytokines or chemokines 
upon activation by pathogens to organize an innate immune attack against the pathogens by 
recruitment or activation of other innate immune cells (82). Third, as an important 
peripheral tolerance mechanism, immature renal DCs constantly capture self antigens from 
the tubules and glomeruli, and even some small molecules which are filtered in glomeruli 
(80, 83-85). Like in other tissue locations, a constant migration of renal DCs into local renal 
lymph nodes probably also exists (86). Through their APC function, the migrated immature 
DCs selectively inhibit activation of potential self reactive T cells. It has been reported that 
additional small self molecules may reach renal lymph nodes, where DCs capture those 
molecules. If these molecules are not associated with pathogenic antigens, they are used to 
tolerize harmful T cells by DCs (87, 88).      
6. DCs in promotion of autoimmune glomerulonephritis 
Like in other peripheral tissues, DCs play a critical role in provoking autoimmunity by 
breaking self tolerance in renal tissues including glomeruli. We have mentioned earlier that 
there are no DCs present in normal glomeruli. What type(s) of DCs are responsible for 
breaking self tolerance and for the maintenance of immune tolerance to glomerular self 
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antigens?  It will be interesting to describe a concept called “tubuloglomerular feedback 
loop” hypothesis (Figure 4). This hypothesis may explain renal DCs’ involvement in both 
self tolerance to tubular/glomerular self antigens, and provoking autoimmune 
inflammatory kidney diseases including glomerulonephritis (84, 89). In steady-state, this 
mechanism may prevent autoimmunity in a similar way to that in mucosal tolerance in the 
intestinal tract, especially for antigens of low molecular mass, although this remains to be 
formally demonstrated (90). A large population of CX3CR1+F4/80+ CD8- DCs, which lines 
the outer medullary tubules to form a DC network, has been described earlier. There is also 
a smaller population of renal CD8+ DCs.  Cellular self antigens released from normal 
apoptotic death or small molecules filtered through glomeruli will reach the lumen of renal 
tubules; tubular epithelial cells will transfer the self antigens to renal CD8- DCs in the 
renal DC network or CD8+ DCs directly uptake those antigens (80, 83-85). The self 
antigens will then be presented to CD4+ T cells by renal CD8- DCs to induce their 
unresponsiveness, or cross-presented by renal CD8+ DCs to CD8+ T cells to induce their 
apoptosis, probably in a similar way to other tissue locations at steady-state (91). Thus, 
tolerance to normally released self glomerular antigens is induced or maintained. On the 
other hand, mechanical/chemical, biological renal injury, or autoimmunity would induce 
cell necrosis, which in turn will release a new set of self antigens called damage-associated 
molecular patterns (DAMPs), some of which could be ligands for TLRs and serve as a 
“danger signal”. When renal DCs pick up and present these DAMPs as danger antigens 
under an inflammatory milieu, they may activate self reactive T cells and cause 
tubulointerstitial inflammation first. The autoimmune response to glomerular antigens will 
be “feedbacked” to the glomerulus either directly or through a periglomerular infiltration. 
One recent study showed that renal DCs could become pathogenic during crescentic 
glomerulonephritis, suggesting that abnormal tissue damages in glomeruli are required for 
differentiation of pro-inflammatory DCs (92). However, it remains unclear where those 
pathogenic DCs originate.   
Studies, which aimed to demonstrate how and what types of renal or non-renal DCs 
participate in pathogenesis of glomerulonephritis, remain scarce. However, it is clear that DCs 
also play a critical role in various renal diseases including autoimmune glomerulonephritis at 
several levels; these roles are mutually related.  First, DCs are required to activate pathogenic T 
cells against renal self antigens.  It is not only true for autoimmune glomerulonephritis, but 
also for other glomerular diseases, as glomerular chronic inflammation may lead to 
autoimmunity. There is evidence that upon encountering maturation stimuli such as DAMPs 
or microbial antigens, renal DCs migrate to the renal draining lymph nodes (86) where they 
activate specific T cells (93). This process is believed to be very similar to the canonical life-
cycle of tissue residing DCs extrapolated from the paradigm of Langerhans cells in the skin 
(73, 91, 94). Activation of self reactive T or B cells in renal draining lymph nodes has been 
demonstrated in animal models for lupus glomerulonephritis and anti-GBM 
glomerulonephritis (95, 96). However, renal DCs or renal infiltrating DCs may also activate T 
cells locally in a lupus model which will be described later. Rodent nephrotoxin nephritis is a 
model for human crescentic glomerulonephritis. Sheep antibody to mouse GBM will be 
“embedded” in the host GBM after injection. GBM-“embedded” sheep antigens are taken up 
by DCs in lymphatic organs, and are used to activate specific Th1 cells and B cells. As a result, 
glomerular inflammation, characteristic of T cell mediated delayed hypersensitivity, occurs.  
Although renal DCs show a protective role at early stages (97), later they act as two types of 
APCs to promote inflammation (60). First, renal DCs migrate to local lymph nodes to cross-
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present glomerular antigens to CD8+ T cells, which in turn cause glomerular damage. Second, 
renal DCs present the self antigen from the damage to CD4+ T cells, which in turn orchestrate 
and maintain glomerular inflammation.  
 
 
Fig. 4. Diagram shows the tubuloglomerular feedback loop under normal and pathologic 
conditions in kidneys.  In normal kidney, self antigens from glomeruli are released to the 
lumen of the tubules. The antigens then are up-take by renal DCs, or transferred to renal 
DCs (arrows) by tubular epithelium. Renal DCs will migrate into renal draining lymph node 
to induce tolerance toward the glomerular antigens.  If renal DCs encounter dangerous 
antigens from glomeruli, they will mature and induce T cell activation. Activated T cells will 
in turn attack glomeruli with dangerous pathogens/antigens by recognition of MHC II-
antigen complex expressed by Bowman’s capsule. 
Second, renal DCs also play a role in establishing glomerular inflammation as an innate 
immune cell. Renal DCs may release a set of pro-inflammatory cytokines and chemokines 
upon stimulation from injuries, and subsequently orchestrate an acute inflammation. It is 
important to re-emphasize that such environmental milieu of acute inflammation may in 
turn provide renal DCs an opportunity to break self tolerance and provoke a pathogenic 
autoimmunity post acute inflammation. Using two models for renal injury, DCs’ roles in 
establishing acute inflammation post renal injury have been investigated in quite detail. 
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Ischaemia-reperfusion injury (IRI) is a model to mimic renal transplantation. Renal F4 ⁄80+ 
CD11c+ subset DCs are the earliest source of TNF- (80), which in turn causes an influx of 
circulating immune cells including pro-inflammatory DC subsets, monocytes ⁄ macrophages 
and T cells (98). Orchestrated actions of these cells contribute to kidney parenchymal 
damage. Renal DCs’ capacity to stimulate T cells remarkably increased 24 hours post renal 
injury (80). Since T cells have been known to play critical roles in IRI (99, 100, 101), as well as 
in glomerular diseases and in transplant rejection, T cell activation by renal DCs may 
contribute to disease progression. One report showed that renal DCs can be activated under 
hypoxia with the transcription factor HIF-1a and LPS (102). However, it remains 
questionable as LPS is not present in the injured renal tissue.  Interestingly, renal DCs may 
also display an anti-inflammatory function in this model, which will be discussed later in 
this section. In the other model, unilateral urethral obstruction results in progressive renal 
fibrosis, which mimics human progressive renal diseases (103).  Although infiltrating 
macrophages, which release the profibrotic and pro-inflammatory cytokines TGF- and 
TNF-, are mainly responsible for renal fibrosis, F4⁄80+ renal DCs are an early source of 
TNF-The importance of this early TNF-from DCs was demonstrated by depletion of 
DCs with Clo-liposome. The depletion led to attenuated renal fibrosis, accompanied by 
reduced TNF- and TGF-levels in obstructed kidneys (104). However, some studies 
suggest that attenuated fibrosis is probably due to a failure in activation of IL-17 secreting 
Th17 or INF--secreting Th1 T cells by renal DCs (105). Thus, DCs may not directly 
participate in fibrosis. However, it needs to be identified which renal DCs are involved in 
the activation of T cells.   
In many cases, renal DCs may play dual roles in tandem in the promotion of autoimmune 
pathogenesis. At earlier stages, renal DCs act as an innate cell to establish an inflammation, and 
at later stages they function as a potent APC to break self tolerance. This is well exemplified by 
lupus glomerulonephritis. Lupus is initiated by glomerular deposition of immune complexes 
formed by autoantibodies and nuclear self antigens, and undergoes two stages during 
progression: antibody-complex mediated acute lupus nephritis and subsequent chronic 
glomerulonephritis with T cell involvement. The roles of DCs in this disease have recently been 
addressed in human patients and animal models. During the first stage, an antibody complex 
triggers complement activation and production of pro-inflammatory cytokines/chemokines, 
leading to acute glomerular inflammation. The roles of DCs in this stage can be summarized as 1) 
a systemic role in breaking T cell tolerance leading to production of autoantibodies, and 2) a local 
role in establishing glomerular inflammation. Because the systemic role of DCs as a APC in 
autoantibody generation is less kidney-specific, we will focus on DCs’ local role. In addition to 
renal DCs, DCs have been found to infiltrate glomeruli in lupus glomerulonephritis (95, 106). At 
least two types of pre-DCs, Gr1+ inflammatory monocyte or Gr1low patrolling monocyte, have 
been found to infiltrate inflamed glomeruli (107). Those infiltrating DCs are able to produce the 
Th1–driving cytokine IL-12 within glomeruli, suggesting their ability to provide a pro-
inflammatory milieu (104). Blockage of co-stimulatory molecules of DCs together with 
cyclophosphamide reduced the number of renal CD11c+ cells, as well as T cell infiltration during 
lupus’ chronic stage. This suggests renal DCs themselves function not only as an innate cell 
population in the promotion/ establishment of renal inflammation but also as APCs to break T 
cell tolerance. It remains unclear how self reactive T cells are primed. T cell activation and 
expansion in the renal draining lymph nodes has been reported, suggesting that migration of 
renal DCs into lymph nodes is necessary (95). Another possibility is that renal DCs may stimulate 
T cells within glomeruli. 
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7. DCs in the prevention of autoimmune glomerulonephritis 
As we discussed earlier, one of the functions for renal DCs in the steady-state is to maintain 
peripheral tolerance to renal self antigens. We also mentioned earlier a concept of 
tubuloglomerular “feedback” loop. This hypothesis may explain how a renal DC network 
maintains self tolerance to glomerular antigens since no DCs are present in this tissue 
location. Thus, self tolerance to glomerular self antigens is established indirectly, in a similar 
way to “oral tolerance”. Consequently, non-dangerous self antigens released from glomeruli 
will be tolerized. This mechanism will prevent glomerular autoimmunity de novo. However, 
recent studies also demonstrated that under acute tissue damage caused by ischemia 
reperfusion, renal DCs still could control inflammation and probably induce tolerance to the 
abnormal self antigens leaked from the damage (108), suggesting that this mechanism may 
also play a role in maintenance of limited self tolerance post acute tissue damages.  
In addition to this renal DC network, several subsets of DCs, including residential and 
infiltrating DCs, also play roles in inhibition of autoimmunity during or post tissue injuries. 
Those renal DCs induce self tolerance or inhibit glomerular inflammation through several 
ways. First, the renal DCs may inhibit autoimmune inflammation in glomeruli as APCs to 
eliminate or anergize pathogenic T cells in glomeruli. In a murine nephrotoxin nephritis 
model, early depletion of CD11c+ cells aggravated renal damage. Because only DCs in mice 
express a high level of CD11c, this study suggested a protective role of renal DCs in 
glomerulonephritis, at least at an early stage of development (97). Mechanistic analysis 
revealed that renal DCs from nephritic mice stimulated a potent T cell proliferation with the 
expression of cytokine IL-10. In general, IL-10 is considered an anti-inflammatory. Further 
study has shown that blockage of IL-10 production aggravated glomerulonephritis. Thus, 
renal DCs during tissue damage may induce differentiation of T cells into an anti-
inflammatory phenotype such as Tregs. A similar phenomenon has been observed in a 
cisplatin induced nephritis model. In this model, renal tubular cells are first damaged by the 
toxin and consequently undergo necrotic cell death. Depletion of CD11c+ cells, which are 
largely murine cDCs but not pDCs, exacerbated renal injury (109). The underlying 
molecular mechanisms may be similar to that in the lung. An increased expression of 
inducible costimulatory ligand (ICOS-L) on DCs can suppress T cells (110). In the above two 
cases, renal cDCs inhibit glomerular inflammation through their APC function to promote 
generation of anti-inflammatory T cells.  Second, renal DCs may also function as anti-
inflammatory immune cells to inhibit autoimmune glomerular inflammation. In a murine 
model, myeloid cells of the kidney, probably renal DCs, have been shown to attenuate 
ischaemia-reperfusion injury, by production of single Ig IL-1-related receptor (SIGIRR) 
(111). SIGIRR is a negative regulator of TLR−IL-1 receptor signaling. It inhibits Th17 T cell 
development, and is an immunosuppressive mediator expressed by DCs and macrophages. 
The deficiency of this mediator worsened tissue damage. This situation could be reversed by 
liposome-mediated depletion of phagocytes including renal DCs, suggesting a potential of 
renal DCs or other renal phagocytes in prevention of further tissue damage by releasing 
anti-inflammatory molecules such as SIGIRR. However, it needs to be proven if renal DCs 
expressing SIGIRR actively contain tissue damage.  Interestingly, a study by the same group 
on a murine lupus model also suggested protective roles in renal injury using SIGIRR-
deficient mice. Mice that lacked SIGIRR showed aggravated hydrocarbon oil-induced lupus 
(112).  
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Despite the above tolerance mechanisms in kidneys, a keen question still remains: why 
abnormal tissue damage such as an infection in glomeruli usually does not result in 
autoimmunity, despite the fact that both cell necrosis and microbial antigens provide 
DAMPs and a danger signal?  Thus, other tolerance mechanisms must exist to prevent 
autoimmunity at the third level (i.e. after self reactive T cells have been activated or 
autoimmune glomerular damage has been initiated). Indeed, a few studies, including one 
from our group, suggest the existence of such DC-mediated tolerance mechanisms. As we 
mentioned before, our group reported a new type of DC with a phenotype of 
CD8αα+CD11b/c+MHC-II+ED1-OX62- in our rat model for anti-GBM glomerulonephritis 
(55). This DC is not residential, but rather is selectively recruited into inflamed glomeruli. 
Both in vivo and in vitro experiments have shown that this DC induces T cell apoptosis in 
the glomeruli, leading to termination of glomerular inflammation (Figure 5). Further 
experiments suggest that this DC is responsible for natural recovery from early 
glomerulonephritis in a disease resistant rat strain by termination of T cell-mediated 
glomerular inflammation (113, unpublished data, Lou). Importantly, transfer of CD8+ DCs 
of a resistant strain cured glomerulonephritis at an early stage in a disease prone strain. This 
mechanism is very attractive and logical, and could be used for development of a novel cell-
based immunotherapeutic strategy for autoimmune glomerulonephritis. DCs have been the 
target for immunotherapy for treating various diseases including cancer and autoimmune 
diseases (114). However, more studies are needed to ensure if a similar mechanism also exits 
in humans (115).  
 
 
Fig. 5. Diagram for the mechanism, by which a new type of CD8+ DC terminates 
glomerular inflammation by active infiltration of inflamed glomeruli and induction of T cell 
apoptosis through Fas-L. Development of this CD8+ DC is also shown. GI CD8+ cells, 
glomeruli-infiltrating CD8+ cells; RT1B, rat MHC II molecule. This model used rats as 
experimental animals.           
8. Conclusive remarks 
Like in other tissue locations, multiple subsets of both cDCs and pDCs reside in normal 
renal tissues both in humans and mice. Heterogeneity of residential renal DCs is due to their 
different precursors and more importantly, renal microenvironmental factors. At a steady-
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state, these residential renal DCs form an immune surveillance network for detecting 
pathogens and for maintaining immune tolerance to renal self antigens. Although glomeruli 
lack residential DCs, those surrounding tubules may monitor antigens from the glomeruli, 
self or non-self, through the tubuloglomerular feedback loop. During acute glomerular 
injury, the majority of residential renal DCs play a critical role in controlling tissue damage 
through their anti-inflammatory function. Under immunological changes in glomeruli, 
including chronic inflammation and autoimmune attacks, both renal residential DCs and 
infiltrating DCs are involved in the process. DCs in the renal draining lymph nodes serve as 
the sole APC to activate naïve self reactive T cells, or those in the renal tissue maintain 
glomerular inflammation by presenting self antigens locally to pathogenic T cells. However, 
tolerogenic DCs inhibit autoimmunity in glomeruli by induction of  anergy or apoptosis in 
self reactive T cells, or by inducing differentiation of regulatory T cells (Tregs). It is 
important to discover new DC subsets, especially tolerogenic DCs, and elucidate their 
differentiation and function.  Using artificially generated tolerogenic DCs, we may be able to 
develop a novel antigen-specific immunotherapeutic strategy for treatment of glomerular 
diseases. 
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